Skip to main content
. 2023 Sep 7;15:659–671. doi: 10.2147/CEOR.S415711

Figure 3.

Figure 3

(A) Cost-effectiveness plane comparing lorlatinib vs alectinib. (B) Cost-effectiveness plane comparing lorlatinib vs brigatinib.

Abbreviations: PSA; probabilistic sensitivity analysis; QALY, quality-adjusted life year; WTP, willingness-to-pay threshold.